A study of alirocumab and ezetimibe in patients with atherosclerotic cardiovascular disease

Trial Profile

A study of alirocumab and ezetimibe in patients with atherosclerotic cardiovascular disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Alirocumab (Primary) ; Ezetimibe (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Dec 2016 New trial record
    • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top